Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Middle East and Africa Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991525
Published Content info 150 Pages
Delivery time: 1-2 business days
Price
Back to Top
Middle East and Africa Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 150 Pages
Description

Middle East and Africa pharmacogenetic testing in psychiatry/depression market is projected to register a CAGR of 7.3% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Middle East and Africa Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (U.A.E., South Africa, Egypt, Saudi Arabia, Israel And Rest Of Middle East and Africa ) Industry Trends & Forecast to 2028.

Some of the major factors contributing to the growth of the Middle East and Africa pharmacogenetic testing in psychiatry/depression market are:

  • Rising demand for precision medicine
  • Advanced methodologies present in the fields

Market Players:

The key market players for Middle East and Africa pharmacogenetic testing in psychiatry/depression market are listed below:

  • STADA Arzneimittel AG
  • AltheaDx
  • Myriad Genetics, Inc.
  • AB-Biotics, S.A.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Sonic Healthcare
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS: MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 5.1 UNITED STATES
    • 5.1.1 ROLE OF FDA
    • 5.1.2 ROLE OF CDC AND HCFA
  • 5.2 EUROPEAN UNION
  • 5.3 FRANCE
  • 5.4 AUSTRALIA
  • 5.5 SOUTH KOREA

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
    • 6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
    • 6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
    • 6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
    • 6.1.5 GROWING MEDICAL TOURISM
  • 6.2 RESTRAINTS
    • 6.2.1 LACK OF STRONG CLINICAL EVIDENCE
    • 6.2.2 HIGH COST
    • 6.2.3 LACK OF REIMBURSEMENT
  • 6.3 OPPORTUNITIES
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS
    • 6.3.2 EMERGENCE OF NEW PLAYERS
    • 6.3.3 UNTAPPED MARKET
  • 6.4 CHALLENGES
    • 6.4.1 STRINGENT GOVERNMENT REGULATION
    • 6.4.2 SHORTAGE OF SKILLED PERSONNEL

7 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 7.1 IMPACT ON PRICE
  • 7.2 IMPACT ON DEMAND
  • 7.3 IMPACT ON SUPPLY
  • 7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 WHOLE GENOME SEQUENCING
  • 8.3 ARRAY-BASED TESTS

9 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

  • 9.1 OVERVIEW
  • 9.2 CYP2C19
  • 9.3 CYP2C9 AND VKORC1
  • 9.4 CYP2D6
  • 9.5 HLA-B
  • 9.6 HTR2A/C
  • 9.7 HLA-A
  • 9.8 CYP3A4
  • 9.9 SLC6A4
  • 9.10 MTHFR
  • 9.11 COMT
  • 9.12 OTHERS

10 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

  • 10.1 OVERVIEW
  • 10.2 PRESCRIPTION DRUGS
  • 10.3 OVER-THE-COUNTER MEDICATIONS
  • 10.4 RECREATIONAL DRUGS
  • 10.5 VITAMINS/NUTRACEUTICALS

11 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

  • 11.1 OVERVIEW
  • 11.2 SALIVA
  • 11.3 BLOOD

12 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION

  • 12.1 OVERVIEW
  • 12.2 DRUG DEVELOPMENT
  • 12.3 CLINICAL PRACTICE

13 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.3 HEALTHCARE PROVIDERS
  • 13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
  • 13.5 OTHERS

14 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 RETAIL PHARMACIES
  • 14.3 HOSPITAL PHARMACIES
  • 14.4 MAIL-ORDER PHARMACIES
  • 14.5 DIRECT-TO-CUSTOMER SERVICES

15 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY

  • 15.1 MIDDLE EAST & AFRICA
    • 15.1.1 SOUTH AFRICA
    • 15.1.2 SAUDI ARABIA
    • 15.1.3 UAE
    • 15.1.4 ISRAEL
    • 15.1.5 EGYPT
    • 15.1.6 REST OF MIDDLE EAST & AFRICA

16 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 MYRIAD GENETICS, INC.
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 THERMO FISHER SCIENTIFIC INC.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 STADA ARZNEIMITTEL AG
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 COMPANY SHARE ANALYSIS
    • 18.3.4 PRODUCT PORTFOLIO
    • 18.3.5 RECENT DEVELOPMENTS
  • 18.4 SONIC HEALTHCARE
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 COMPANY SHARE ANALYSIS
    • 18.4.4 PRODUCT PORTFOLIO
    • 18.4.5 RECENT DEVELOPMENT
  • 18.5 ILLUMINA, INC.
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 COMPANY SHARE ANALYSIS
    • 18.5.4 PRODUCT PORTFOLIO
    • 18.5.5 RECENT DEVELOPMENTS
  • 18.6 AB-BIOTICS, S.A.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 6.3 PRODUCT PORTFOLIO
    • 18.6.4 RECENT DEVELOPMENTS
  • 18.7 ALTHEADX
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 PRODUCT PORTFOLIO
    • 18.7.3 RECENT DEVELOPMENT
  • 18.8 BIOGENIQ INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 PRODUCT PORTFOLIO
    • 18.8.3 RECENT DEVELOPMENT
  • 18.9 COLOR
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 PRODUCT PORTFOLIO
    • 18.9.3 RECENT DEVELOPMENTS
  • 18.10 CNSDOSE
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 CORIELL LIFE SCIENCES
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 PRODUCT PORTFOLIO
    • 18.11.3 RECENT DEVELOPMENTS
  • 18.12 DYNAMIC DNA LABORATORIES
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 PRODUCT PORTFOLIO
    • 18.12.3 RECENT DEVELOPMENTS
  • 18.13 GENELEX
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 PRODUCT PORTFOLIO
    • 18.13.3 RECENT DEVELOPMENT
  • 18.14 GENOMIND, INC.
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 PRODUCT PORTFOLIO
    • 18.14.3 RECENT DEVELOPMENTS
  • 18.15 GENXYS
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 PRODUCT PORTFOLIO
    • 18.15.3 RECENT DEVELOPMENTS
  • 18.16 HEALTHSPEK
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 PRODUCT PORTFOLIO
    • 18.16.3 RECENT DEVELOPMENT
  • 18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 PRODUCT PORTFOLIO
    • 18.17.3 RECENT DEVELOPMENT
  • 18.18 LUMINEX CORPORATION
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENTS
  • 18.19 MILLENNIUM HEALTH
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 PRODUCT PORTFOLIO
    • 18.19.3 RECENT DEVELOPMENTS
  • 18.20 MYDNA LIFE AUSTRALIA PTY LTD.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 PRODUCT PORTFOLIO
    • 18.20.3 RECENT DEVELOPMENT
  • 18.21 ONEOME
    • 18.21.1 COMPANY SNAPSHOT
    • 18.21.2 PRODUCT PORTFOLIO
    • 18.21.3 RECENT DEVELOPMENTS
  • 18.22 OMECARE
    • 18.22.1 COMPANY SNAPSHOT
    • 18.22.2 PRODUCT PORTFOLIO
    • 18.22.3 RECENT DEVELOPMENT
  • 18.23 PERKINELMER INC.
    • 18.23.1 COMPANY SNAPSHOT
    • 18.23.2 REVENUE ANALYSIS
    • 18.23.3 PRODUCT PORTFOLIO
    • 18.23.4 RECENT DEVELOPMENTS
  • 18.24 R-BIOPHARM AG
    • 18.24.1 COMPANY SNAPSHOT
    • 18.24.2 PRODUCT PORTFOLIO
    • 18.24.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)
  • TABLE 2 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 MIDDLE EAST AND AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)
  • TABLE 5 MIDDLE EAST AND AFRICA CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 MIDDLE EAST AND AFRICA CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 MIDDLE EAST AND AFRICA CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 MIDDLE EAST AND AFRICA HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 MIDDLE EAST AND AFRICA HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 MIDDLE EAST AND AFRICA HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 MIDDLE EAST AND AFRICA CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 MIDDLE EAST AND AFRICA SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 13 MIDDLE EAST AND AFRICA MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 MIDDLE EAST AND AFRICA COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 MIDDLE EAST AND AFRICA OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)
  • TABLE 17 MIDDLE EAST AND AFRICA PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 MIDDLE EAST AND AFRICA OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 MIDDLE EAST AND AFRICA RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 MIDDLE EAST AND AFRICA VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)
  • TABLE 22 MIDDLE EAST AND AFRICA SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 23 MIDDLE EAST AND AFRICA BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)
  • TABLE 25 MIDDLE EAST AND AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 MIDDLE EAST AND AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)
  • TABLE 28 MIDDLE EAST AND AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 MIDDLE EAST AND AFRICA HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 MIDDLE EAST AND AFRICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)
  • TABLE 33 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 35 MIDDLE EAST AND AFRICA MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))
  • TABLE 36 MIDDLE EAST AND AFRICA DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 41 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 42 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 43 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 45 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 46 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 47 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 48 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 49 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 50 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 51 SOUTH AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 52 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 53 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 54 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 55 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 56 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 57 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 58 SAUDI ARABIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 59 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 60 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 61 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 62 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 63 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 64 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 65 UAE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 66 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 67 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 68 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 70 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 71 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 72 ISRAEL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 73 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 74 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 75 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 76 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 77 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 78 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 79 EGYPT PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 80 REST OF MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST AND AFRICA PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 2 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DATA TRIANGULATION
  • FIGURE 3 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET APPLICATION COVERAGE GRID
  • FIGURE 9 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 11 INITIATIVES TAKEN BY MANUFACTURERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2021 & 2028
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • FIGURE 14 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
  • FIGURE 15 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
  • FIGURE 16 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 17 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 18 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
  • FIGURE 19 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
  • FIGURE 20 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
  • FIGURE 21 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
  • FIGURE 22 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
  • FIGURE 23 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
  • FIGURE 24 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 25 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
  • FIGURE 26 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
  • FIGURE 27 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • FIGURE 28 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 29 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
  • FIGURE 30 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
  • FIGURE 31 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
  • FIGURE 32 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
  • FIGURE 33 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 34 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
  • FIGURE 35 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
  • FIGURE 36 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 37 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 38 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
  • FIGURE 39 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • FIGURE 40 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 41 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 42 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 43 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 44 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 45 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 46 MIDDLE EAST & AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 47 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
Back to Top